Lundbeck CEO expects migraine market to grow following Pfizer's billion-dollar acquisition

The USD 11.6bn acquisition bid for migraine firm Biohaven Pharmaceuticals would make Pfizer a direct competitor to Lundbeck. Even so, ”the migraine market is so big and so unsatisfied that there is room for multiple therapies,” says CEO Deborah Dunsire.
Deborah Dunsire, CEO of Lundbeck | Photo: Gregers Tycho/ERH
Deborah Dunsire, CEO of Lundbeck | Photo: Gregers Tycho/ERH
by christian bundgaard, translated by daniel pedersen

Lundbeck’s sales performance within its strategic brands was strong in the year’s first quarter, during which three out four of the firm’s key drugs beat analysts’ expectations.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading